Cargando…
Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1
Neurofibromatosis Type 1 (NF1) is a genetic disease caused by mutations in Neurofibromin 1 (NF1). NF1 patients present with a variety of clinical manifestations and are predisposed to cancer development. Many NF1 animal models have been developed, yet none display the spectrum of disease seen in pat...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168575/ https://www.ncbi.nlm.nih.gov/pubmed/30302402 http://dx.doi.org/10.1038/s42003-018-0163-y |
_version_ | 1783360378269335552 |
---|---|
author | Isakson, Sara H. Rizzardi, Anthony E. Coutts, Alexander W. Carlson, Daniel F. Kirstein, Mark N. Fisher, James Vitte, Jeremie Williams, Kyle B. Pluhar, G. Elizabeth Dahiya, Sonika Widemann, Brigitte C. Dombi, Eva Rizvi, Tilat Ratner, Nancy Messiaen, Ludwine Stemmer-Rachamimov, Anat O. Fahrenkrug, Scott C. Gutmann, David H. Giovannini, Marco Moertel, Christopher L. Largaespada, David A. Watson, Adrienne L. |
author_facet | Isakson, Sara H. Rizzardi, Anthony E. Coutts, Alexander W. Carlson, Daniel F. Kirstein, Mark N. Fisher, James Vitte, Jeremie Williams, Kyle B. Pluhar, G. Elizabeth Dahiya, Sonika Widemann, Brigitte C. Dombi, Eva Rizvi, Tilat Ratner, Nancy Messiaen, Ludwine Stemmer-Rachamimov, Anat O. Fahrenkrug, Scott C. Gutmann, David H. Giovannini, Marco Moertel, Christopher L. Largaespada, David A. Watson, Adrienne L. |
author_sort | Isakson, Sara H. |
collection | PubMed |
description | Neurofibromatosis Type 1 (NF1) is a genetic disease caused by mutations in Neurofibromin 1 (NF1). NF1 patients present with a variety of clinical manifestations and are predisposed to cancer development. Many NF1 animal models have been developed, yet none display the spectrum of disease seen in patients and the translational impact of these models has been limited. We describe a minipig model that exhibits clinical hallmarks of NF1, including café au lait macules, neurofibromas, and optic pathway glioma. Spontaneous loss of heterozygosity is observed in this model, a phenomenon also described in NF1 patients. Oral administration of a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor suppresses Ras signaling. To our knowledge, this model provides an unprecedented opportunity to study the complex biology and natural history of NF1 and could prove indispensable for development of imaging methods, biomarkers, and evaluation of safety and efficacy of NF1-targeted therapies. |
format | Online Article Text |
id | pubmed-6168575 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-61685752018-10-09 Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 Isakson, Sara H. Rizzardi, Anthony E. Coutts, Alexander W. Carlson, Daniel F. Kirstein, Mark N. Fisher, James Vitte, Jeremie Williams, Kyle B. Pluhar, G. Elizabeth Dahiya, Sonika Widemann, Brigitte C. Dombi, Eva Rizvi, Tilat Ratner, Nancy Messiaen, Ludwine Stemmer-Rachamimov, Anat O. Fahrenkrug, Scott C. Gutmann, David H. Giovannini, Marco Moertel, Christopher L. Largaespada, David A. Watson, Adrienne L. Commun Biol Article Neurofibromatosis Type 1 (NF1) is a genetic disease caused by mutations in Neurofibromin 1 (NF1). NF1 patients present with a variety of clinical manifestations and are predisposed to cancer development. Many NF1 animal models have been developed, yet none display the spectrum of disease seen in patients and the translational impact of these models has been limited. We describe a minipig model that exhibits clinical hallmarks of NF1, including café au lait macules, neurofibromas, and optic pathway glioma. Spontaneous loss of heterozygosity is observed in this model, a phenomenon also described in NF1 patients. Oral administration of a mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor suppresses Ras signaling. To our knowledge, this model provides an unprecedented opportunity to study the complex biology and natural history of NF1 and could prove indispensable for development of imaging methods, biomarkers, and evaluation of safety and efficacy of NF1-targeted therapies. Nature Publishing Group UK 2018-10-02 /pmc/articles/PMC6168575/ /pubmed/30302402 http://dx.doi.org/10.1038/s42003-018-0163-y Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Isakson, Sara H. Rizzardi, Anthony E. Coutts, Alexander W. Carlson, Daniel F. Kirstein, Mark N. Fisher, James Vitte, Jeremie Williams, Kyle B. Pluhar, G. Elizabeth Dahiya, Sonika Widemann, Brigitte C. Dombi, Eva Rizvi, Tilat Ratner, Nancy Messiaen, Ludwine Stemmer-Rachamimov, Anat O. Fahrenkrug, Scott C. Gutmann, David H. Giovannini, Marco Moertel, Christopher L. Largaespada, David A. Watson, Adrienne L. Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 |
title | Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 |
title_full | Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 |
title_fullStr | Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 |
title_full_unstemmed | Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 |
title_short | Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 |
title_sort | genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168575/ https://www.ncbi.nlm.nih.gov/pubmed/30302402 http://dx.doi.org/10.1038/s42003-018-0163-y |
work_keys_str_mv | AT isaksonsarah geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT rizzardianthonye geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT couttsalexanderw geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT carlsondanielf geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT kirsteinmarkn geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT fisherjames geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT vittejeremie geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT williamskyleb geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT pluhargelizabeth geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT dahiyasonika geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT widemannbrigittec geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT dombieva geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT rizvitilat geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT ratnernancy geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT messiaenludwine geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT stemmerrachamimovanato geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT fahrenkrugscottc geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT gutmanndavidh geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT giovanninimarco geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT moertelchristopherl geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT largaespadadavida geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 AT watsonadriennel geneticallyengineeredminipigsmodelthemajorclinicalfeaturesofhumanneurofibromatosistype1 |